HA–EDA–Pt( iv ) nanoconjugates were constructed, characterized, and proved as an safe formulation with better blood compatibility and less systemic toxicity.
No takes yet. Share an insight, caveat, or question.
Ling et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: